Should Mason, Ohio-based Assurex hit specific performance goals, the deal could reach up to $410 million.
The transaction is set to close in October.
Mayo financed Assurex’s most profitable medical device, GeneSight, a test that analyzes psychiatric patients’ genes to determine the best antidepressant and antipsychotic drugs to treat the patient. Mayo has forfeited its intellectual property license for the test in the sale, but the clinic may still retain some investment.
Assurex launched in 2006. More than 450 employees will retain their jobs. Officials plan to keep Assurex’s headquarters in Ohio.
More articles on transactions and valuations:
Next Life Medical Acquires Emergent Respiratory
Mount Sinai Health partners with Stony Brook Medicine
AltaPointe merges with Cheaha Regional Mental Health
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.